AM J PSYCHIAT:疼痛了吗?小心阿片类药物成瘾!

2016-07-24 fsy 译 MedSci原创

对于疼痛的经历和阿片类药物使用障碍的风险之间的关系,我们又知道多少呢?最近的一项研究结果表明(第一项直接解决这个问题的研究),患有中度或较严重疼痛的人群,处方阿片类药物使用障碍的风险比那些没有疼痛的人群高41%,并且这种关系是独立于其他人口和临床因素的。来自哥伦比亚大学医学中心的研究人员进行了这项研究,该研究被刊登在美国精神病学杂志(American Journal of Psychiatry)上

对于疼痛的经历和阿片类药物使用障碍的风险之间的关系,我们又知道多少呢?最近的一项研究结果表明(第一项直接解决这个问题的研究),患有中度或较严重疼痛的人群,处方阿片类药物使用障碍的风险比那些没有疼痛的人群高41%,并且这种关系是独立于其他人口和临床因素的。

来自哥伦比亚大学医学中心的研究人员进行了这项研究,该研究被刊登在美国精神病学杂志(American Journal of Psychiatry)上。

研究人员在两次调查中,分析了34,000多名成人关于酒精和物质滥用的一项全国性调查数据,两次调查相隔3年。在每一个点,他们都研究了疼痛(日常活动中疼痛相关干扰的五分量表),处方阿片类药物的使用障碍,以及其他变量,如年龄、性别、焦虑或情绪障碍,和家族史、酒精、和行为问题。

报告疼痛和有处方阿片类药物使用障碍的参与者与其他参与者相比,更可能会报告最近的物质滥用,情绪或焦虑症或酒精使用障碍的家族史。

“这些发现表明,报告中度或较严重疼痛的成年人正在处于处方阿片类药物成瘾风险增加的状态,”该报告的作者,美国哥伦比亚大学医学中心的精神病学教授,医学博士Mark Olfson说。“考虑到全国阿片类药物滥用的流行,这些新结果强调了制定有效的、多模式的方法来管理疼痛医疗条件的重要性。”

男性和年轻成年人正处于处方阿片类药物使用障碍风险增加的状态,这一发现证实了以前的研究结果的结论。此外,女性和老年人更可能会报告疼痛。

“在出现疼痛的患者中,医生也应注意到成瘾的危险因素,如年龄、性别和药物滥用以及个人史或家族史,”Olfson博士补充说。“如果开具阿片类药物处方,临床医生应仔细监测患者对阿片类药物成瘾的迹象。”

原始出处:

Carlos Blanco, Melanie M. Wall, Mayumi Okuda, Shuai Wang, Miren Iza, Mark Olfson. Pain as a Predictor of Opioid Use Disorder in a Nationally Representative Sample. American Journal of Psychiatry, 2016.7.23

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
    2016-09-14 1e10c84am36(暂无匿称)

    文章不错,值得拜读

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
    2016-09-06 李东泽

    很好,不错,以后会多学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
    2016-09-03 doctorJiangchao

    继续关注路

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
    2016-09-03 doctorJiangchao

    继续学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
    2016-08-03 oo902

    可怕,当心

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1695699, encodeId=12f81695699b0, content=<a href='/topic/show?id=a6948e7452c' target=_blank style='color:#2F92EE;'>#药物成瘾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87745, encryptionId=a6948e7452c, topicName=药物成瘾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e6429864127, createdName=tidiq, createdTime=Sun Jan 08 09:36:00 CST 2017, time=2017-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126767, encodeId=1f7f126e67c5, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:55:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=112772, encodeId=fd19112e7236, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Sep 06 23:50:00 CST 2016, time=2016-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110438, encodeId=5cb511043842, content=继续关注路, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:19:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=110437, encodeId=e0b511043e41, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Sep 03 18:18:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95741, encodeId=ee2295e41a2, content=可怕,当心, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Aug 03 17:03:00 CST 2016, time=2016-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253010, encodeId=e5c312530101d, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309024, encodeId=309b13090241a, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Tue Jul 26 13:36:00 CST 2016, time=2016-07-26, status=1, ipAttribution=)]
    2016-07-26 lhlxtx

相关资讯

小知识:乳房疼痛八种原因,你知道多少?

所有年龄段的女性都存在不同程度的乳房疼痛(也称为乳腺痛)。绝经期前后会发生疼痛,然而,乳房疼痛最常见于青年女性月经来潮时。 近70%的女性自诉曾出现乳房疼痛,只有约15%就诊并寻求治疗。 乳房疼痛的严重程度和位置各有不同。疼痛可发生在两个乳房或单侧乳房或腋下。严重程度从轻微到严重不等。月经、怀孕、哺乳、更年期等时期出现的激素变化也会影响乳房疼痛。 以下是乳房疼痛的八大常见原因:1.乳腺囊肿 临床上

Dermatol Surg:Dysport治疗皱纹的有效性和安全性研究

根据最近发表的研究结果,双倍Dysport注射量与标记注射量相比,相同单位剂量治疗女性面部皱纹是有效和安全的。研究人员对62名30岁至63岁女性进行了研究,女性接受了2种不同注射剂量的Dysport(abobotulinumtoxinA, Galderma),在欧洲以Azzalure (Ipsen Biopharm Limited)销售,用于眉间纹的治疗。标记注射量是使用0.63 mL 0.9%

Health Affair:医用大麻合法化降低了处方药的使用

发表在Health Affairs的研究称,在美国的一些州医用大麻合法化减少了处方药的使用,相当于2013年节省了超过1亿6500万美元。截至上个月,美国共有25个州和华盛顿特区针对某些健康问题(如神经性疼痛和痉挛)对大麻合法化。在2013年时,美国有17个会州和华盛顿特区合法化医用大麻。美国食品和药物管理局(FDA)并没有急于科学证据批准大麻,目前还不知道大麻的有效性和安全性。大麻的合法化是基于

阿尔兹海默病和其他类型痴呆患者疼痛的识别和管理

阿尔兹海默病患者的疼痛及疼痛管理是一项复杂的问题。2016年6月,发表在《CNS Drugs.》的一项系统评价对阿尔兹海默病和其他类型痴呆患者疼痛的识别和管理进行分析。背景和目的:阿尔兹海默病患者的疼痛是一项复杂的问题,这些患者会遭受常见病因的急性和慢性疼痛,一些也具有神经性或伤害性疼痛。无论这些患者中的疼痛机制如何,他们的疼痛都将需要仔细的评估和管理,从而确保给予了正确的镇痛类型和镇痛水平。本系

Trends Cognitive Science:希望也能治病

着装反映了社会预期对性别的影响。图片来源:KATHARINA SCHWARZ对于很多人而言,期望具有不小的力量,而这也被安慰剂研究所证实:患者服用没有有效成分的药物,但他们并不知道。如果坚信服用的是有效药物,他们的症状确实在好转。而这只是预期心理在起作用。“在治疗疼痛和抑郁时,安慰剂的效果通常很好。”德国巴伐利亚州詹姆斯·麦迪逊大学(JMU)心理学研究所教授Katharina Schwarz说。仅

J Am Acad Dermatol:约三分之一的患者在Mohs显微外科手术中经历疼痛

近期发表在Journal of the American Academy of Dermatology的研究称,在Mohs显微外科手术的一天约三分之一的患者报道疼痛,大多数患者报告的疼痛程度低。纽约Memorial Sloan-Kettering癌症中心皮肤病学 的Karen L. Connolly博士和同事要求患者出院时报告Mohs显微外科手术中疼痛情况(0和10之间的范围)。在研究的第二阶段,